Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development ...

Pfizer cuts losses on near-approval hemophilia gene therapy, adding to troubled Sangamo's woes Pfizer plans to share the results at an upcoming medical congress. Areas of interest beyond the ...

[Click here for information about joining the class action] During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A ...

Sangamo Therapeutics regained development and commercialization rights for its hemophilia A candidate, giroctocogene fitelparvovec, after partner Pfizer conveyed its decision to terminate their ...

In addition to the Genentech partnership, Sangamo continues to work closely with Pfizer (NYSE:PFE) on the development of giroctogene fitelparvovec (giro-vec), a gene therapy for hemophilia A. Positive ...

In addition to the Genentech partnership, Sangamo continues to work closely with Pfizer (NYSE:PFE) on the development of giroctogene fitelparvovec (giro-vec), a gene therapy for hemophilia A.

What Happened? On December 30, 2024, after market hours, Sangamo disclosed that Pfizer Inc. (“Pfizer”) had notified the Company of its termination of a partnership to develop a hemophilia A ...